MEA Respiratory Inhaler Market

Middle East & Africa Respiratory Inhaler Market Size & Growth (2023 to 2028)

As per the research report, the size of the Middle East and Africa Respiratory Inhaler market is valued at USD XX billion in 2023 and is expected to reach USD XX billion by 2028 at XX% CAGR during the forecast period 2023 to 2028.

Infectious respiratory diseases directly determine the demand for respiratory inhalers. Respiratory diseases like pneumonia, Chronic Obstructive Pulmonary Disease (COPD), asthma and COVID-19 is the most recent infections resulting in driving the market.

According to a 2018 report from the Global Initiative for Chronic Obstruction Disease, COPD is anticipated to cause 4.52 million deaths per year globally by 2030. Demand for has inhalers has increased due to the COVID-19 outbreak, which has led to government and industry support to accelerate the pace of manufacturing.

Other factors like the rapid growth of the geriatric population, improving healthcare facilities and the economic benefits in home care setting and services are also responsible for driving the growth of the market.

The high growth potential in MEA region due to support for emerging markets, cheaper labor when compared to western countries and the evolution of miniaturized devices are anticipated to provide significant growth opportunities for market players. With recent foreign investments, the health scenario is improving in the MEA region. Therefore, the market for this region, although it is not large, is anticipated to grow in the future.

However, factors such as the lack of reimbursement policies and the availability of low cost products from local manufacturers are anticipated to restrain the growth of this market during the forecast period.

 In addition, the increasing adoption of alternative therapies, such as oral medications or subcutaneous injections will slow down the market growth. There is scarcity of knowledge on the use of these respiratory inhalers as well as the administration protocols will limit the growth of the MEA respiratory inhalers market.

This research report on the MEA Respiratory Inhaler Market has been segmented and sub-segmented into the following categories.

By Product:

• Dry Powder Inhaler
• Metered Dose Inhaler
• Nebulizer

By Technology:

• Manually Operated Inhaler Devices
• Digitally Operated Inhaler Devices

By Disease Indication:

• Asthma
• COPD
• Pulmonary Arterial Hypertension
• Others Respiratory Disease

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, the Middle East & Africa Respiratory Inhaler Market leads the market globally due to the strong presence of established players in the region.

Several factors which have appositive effect on the growth of these regional markets includes the presence of advanced health infrastructure, large patient population suffering from COPD and increased health spending.

The UAE Respiratory Inhaler Market is the largest share of the MEA Respiratory Inhaler Market. On the other hand, other parts of the region which are not yet well developed have less contribution to the growth of respiratory inhalers in the Middle East region.

The Africa region is, overall, the least developed region with limited health care resources and facilities. Despite the high prevalence of respiratory diseases, such as asthma and COPD, they remain largely underdiagnosed and undertreated.

The Saudi Arabia Respiratory Inhaler Market is projected to grow at a highest CAGR due to the low awareness of these diseases and the lack of availability of adequate resources to diagnose and treat.

According to the WHO, more than 90% of deaths from COPD and 80% of deaths from asthma occur in low- and middle-income countries. It is estimated that about 70% of patients with COPD are underdiagnosed due to ignorance of the disease.

KEY MARKET PLAYERS

Leading companies dominating the MEA Respiratory Inhaler Market profiled in the report are AstraZeneca, Beximco Pharmaceuticals Ltd., Merck & Co., Inc., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc, Koninklijke Philips N.V., OMRON Healthcare Europe B.V., PARI Medical Holding and Teva Pharmaceutical Industries Ltd.